Drug-Drug Interactions With Anticoagulants or Other Drugs/Substances
Involved With Clotting
humanised IgG4 monoclonal antibody, galcanezumab is expected to be
degraded into small peptides and amino acids via catabolic pathways
in the same manner as endogenous IgG.1,2
such, it is not expected to
metabolic or induce enzymatic pathways
metabolized by the cytochrome P450 families of drug-metabolizing
any active metabolites.2-4
Interactions Studies Were Not Conducted
drug interaction studies were conducted. No pharmacokinetic drug
interactions are expected based on the characteristics of
are no known interactions for galcanezumab, drug-drug or otherwise.3
Emgality [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and
pharmacodynamic insights into monoclonal antibodies with a focus on
galcanezumab, an anti-CGRP antibody. Cephalalgia.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and
pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668.
= calcitonin gene-related peptide
= immunoglobulin G
= immunoglobulin G (subclass) 4
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.